Yann Cotte’s Post

Unlock the potential of academic research innovation hubs and AI in pharmaceutical drug R&D with OniX. Discover how OniX bridges the gap between groundbreaking academic research and industry application to accelerate drug development in our latest blog post https://lnkd.in/eKGKEraQ

In this interview with Tom Zhang, Worldwide Clinical Trials' Chief Scientific Officer of Large Molecule Bioanalysis, we gain a behind the scenes glimpse into how they are collaboratively partnering with biotech and pharmaceutical companies to aid research and embrace innovation. Watch now >>> https://hubs.ly/Q02HM1q00

SDBN Trending News: The top biopharma conferences in 2025 https://lnkd.in/gVqUeDDb With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented and dissected at medical conferences throughout the year. These are the forums where executives get [...]

SDBN Feed: The top biopharma conferences in 2025 https://lnkd.in/gff3Uv9q With rare exceptions, biotechnology and pharmaceutical companies validate their business plans through clinical trials, results from which are often presented and dissected at medical conferences throughout the year. These are the forums where executives get [...]

Hello connections! As participation is the first step towards success, I am delighted to share that I have participated in a webinar 'AI-Driven Predictive Modeling in Drug Discovery: Boosting Accuracy and Speed in Identifying Drug Candidates' organized by Society of Pharmaceutical Sciences and Research (SPSR). The session was very informative and it gave me a lot of knowledge about Computer Aided Drug Discovery and Pharmaceutical Research. #drugdiscovery #pharmaceuticalresearch #molecularmodeling #mdsimulation #researchanddevelopment #moleculardynamics

AI is improving speed and reducing costs at every stage of the drug discovery and development process 💊 Rachel Brazil's article for Pharmaceutical Journal Publications explores how AI is accelerating drug discovery, enhancing precision oncology, and cutting costs. From identifying novel targets to streamlining clinical trials, AI is transforming the pharmaceutical industry. Read more about how companies like Recursion, Lantern Pharma Inc. (Nasdaq: LTRN), and BenevolentAI are leading this journey at https://lnkd.in/gBSNG_at #AI #DrugDiscovery #Pharma #Innovation #Pharmaceuticals #AIforDrugDiscovery #AIforHealthcare

An optimal #protein target is one that is 1) mechanistically involved in disease pathogenesis, 2) uniquely or differentially expressed in diseased cells, and 3) tractable, with properties that allow it to be modulated by the drug. In this #webinar, hosted by American Association of Pharmaceutical Scientists (AAPS) | @aapscomms, we will discuss how mass spectrometry-based discovery #proteomics combined with #AI-based target validation can be used to comprehensively characterize the expanded breadth of potential protein targets to identify the best target for a given therapy. Register now to join us and speaker Mo Jain, MD PhD for the live discussion on September 18th: https://lnkd.in/gUGxd22a #targetdiscovery #targetidentification #targetvalidation

Earlier today, I had a productive discussion with Dr. Ada Gabriel about his research on anti-snake venom at the Pharmacognosy Lab, Department of Pharmaceutical Sciences, Ahmadu Bello University Zaria. We explored various ways in which AI can be implemented to redefine drug discovery.

AI-Powered Drug Discovery: Revolutionizing Medicine" MIT researchers have developed the SPARROW algorithm, which leverages AI to identify the most promising molecules for new medicines. This innovative approach significantly speeds up the drug discovery process, potentially leading to faster development of life-saving treatments. Read more about how AI is transforming the pharmaceutical industry here: https://lnkd.in/gD-PX5mE

Developing precision therapeutics requires understanding complex diseases at the molecular level. A powerful way to gather the required data is via multiomic analyses of human fluid reservoirs such as peripheral blood plasma, or “liquid biopsy”. Discover how we work with pharmaceutical companies to enable therapeutic innovation: https://lnkd.in/ehCYgW8J